Rising US drug expenditures are driven primarily by spending on specialty biologic drugs. From 2014 to 2018 alone, spending on biologic drugs increased 50% to $125 billion (1). Growing spending reflects rising biologic drug prices, not just increased use. Many policy analysts, including the Congressional Budget Office (CBO), forecasted that biosimilars would curb spending by finally introducing competition into the marketplace.

中文翻译：

---

发布失败：美国的生物仿制药销售继续下滑。

美国药品支出的增长主要由特种生物药品支出驱动。仅从2014年到2018年，生物药品支出就增长了50％，达到1250亿美元（1）。支出的增加反映了生物药物价格的上涨，而不仅仅是增加了使用量。包括国会预算办公室（CBO）在内的许多政策分析人士预测，生物仿制药将通过最终将竞争引入市场来抑制支出。